About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is a company based in Singapore (Singapore) founded in 2010. ASLAN Pharmaceuticals has raised $100 million across 9 funding rounds from investors including Haitong International Securities Group, Tianda Pharmaceutical and K2 HealthVentures. ASLAN Pharmaceuticals operates in a competitive market with competitors including UNION Therapeutics, Concerto Biosciences, Biosion, Forte Biosciences and PinCell, among others.
- Headquarter Singapore, Singapore
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aslan Pharmaceuticals Pte Ltd
-
Annual Revenue
Not available
-
Net Profit
-$46.34 M (USD)-55as on Dec 31, 2022
-
EBITDA
-$45.89 M (USD)-57as on Dec 31, 2022
-
Total Equity Funding
$100 M (USD)
in 9 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Mar 02, 2023
-
Investors
Haitong International Securities Group
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ASLAN Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of ASLAN Pharmaceuticals
ASLAN Pharmaceuticals has successfully raised a total of $100M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ASLAN Pharmaceuticals
ASLAN Pharmaceuticals has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Haitong International Securities Group, Tianda Pharmaceutical and K2 HealthVentures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Flexible, long-term financing solutions are provided to healthcare companies.
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Top Taiwan.
|
Locked | Locked | Locked |
Investor details for ASLAN Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ASLAN Pharmaceuticals
Investment portfolio details for ASLAN Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ASLAN Pharmaceuticals
Detailed financials for ASLAN Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aslan Pharmaceuticals Comparisons
Peer comparison for ASLAN Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ASLAN Pharmaceuticals
ASLAN Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as UNION Therapeutics, Concerto Biosciences, Biosion, Forte Biosciences and PinCell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule antibiotics are developed for bacterial infections.
|
|
| Locked | Locked | Locked |
Microbe-based products are developed for agriculture and human health.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of anti-inflammatory therapy for the treatment skin diseases
|
Detailed competitors of ASLAN Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aslan Pharmaceuticals
Complete news archive for ASLAN Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ASLAN Pharmaceuticals
ASLAN Pharmaceuticals was founded in 2010.
ASLAN Pharmaceuticals is headquartered in Singapore, Singapore.
ASLAN Pharmaceuticals is a funded company, having raised a total of $100M across 9 funding rounds to date.
ASLAN Pharmaceuticals was founded in 2010 in Singapore as an oncology-focused entity. Targeted drugs are developed for gastric, bile duct, and breast cancers through a proprietary pipeline of four candidates. These address indications including gastric and breast cancers plus inflammatory diseases. ASLAN001, a pan-HER inhibitor, advances in phase 2 for gastric cancer and extends to cholangiocarcinoma and breast cancer. ASLAN002 targets RON and cMET receptors for gastric and breast applications.
ASLAN Pharmaceuticals's top competitors include Concerto Biosciences, UNION Therapeutics and Biosion.
ASLAN Pharmaceuticals has 14 investors. Key investors include Haitong International Securities Group, Tianda Pharmaceutical, K2 HealthVentures, BVF Partners, and Top Taiwan.